Form D · Biotechnology
Healix Clinical Laboratory LLC
Bellaire, TX · CIK 0001982918
Offering snapshot reported Jul 5, 2023 · SEC filing
- Reported sold
- $2M Offering amount: $2.75M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $100K Reported outside-investor minimum
- First sale
- May 5, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 5, 2023 | Initial | $2,000,000 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-485893
Convertible Debt
Source: Form D, filed Jul 5, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter K. Bryant Greenwood | Director, Executive |
| Elenora Huber | Director |
| Marc Mintz | Director |
| Michael Niccolini | Director |
| Kevin P. Rosenblatt | Director, Executive |
| Shea C. Spruill | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4800 Fournace Place Suite Bw3
Bellaire, TX, 77401
Bellaire, TX, 77401